Cargando…
The impact of complex karyotype on the overall survival of patients with relapsed chronic lymphocytic leukemia treated with idelalisib plus rituximab
| Autores principales: | , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7214265/ https://www.ncbi.nlm.nih.gov/pubmed/31427720 http://dx.doi.org/10.1038/s41375-019-0533-6 |
| _version_ | 1783531930502823936 |
|---|---|
| author | Kreuzer, Karl-Anton Furman, Richard R. Stilgenbauer, Stephan Dubowy, Ronald L. Kim, Yeonhee Munugalavadla, Veerendra Lilienweiss, Esther Reinhardt, Hans Christian Cramer, Paula Eichhorst, Barbara Hillmen, Peter O’Brien, Susan M. Pettitt, Andrew R. Hallek, Michael |
| author_facet | Kreuzer, Karl-Anton Furman, Richard R. Stilgenbauer, Stephan Dubowy, Ronald L. Kim, Yeonhee Munugalavadla, Veerendra Lilienweiss, Esther Reinhardt, Hans Christian Cramer, Paula Eichhorst, Barbara Hillmen, Peter O’Brien, Susan M. Pettitt, Andrew R. Hallek, Michael |
| author_sort | Kreuzer, Karl-Anton |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7214265 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2019 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-72142652020-05-14 The impact of complex karyotype on the overall survival of patients with relapsed chronic lymphocytic leukemia treated with idelalisib plus rituximab Kreuzer, Karl-Anton Furman, Richard R. Stilgenbauer, Stephan Dubowy, Ronald L. Kim, Yeonhee Munugalavadla, Veerendra Lilienweiss, Esther Reinhardt, Hans Christian Cramer, Paula Eichhorst, Barbara Hillmen, Peter O’Brien, Susan M. Pettitt, Andrew R. Hallek, Michael Leukemia Letter Nature Publishing Group UK 2019-08-19 2020 /pmc/articles/PMC7214265/ /pubmed/31427720 http://dx.doi.org/10.1038/s41375-019-0533-6 Text en © The Author(s) 2019 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution, and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
| spellingShingle | Letter Kreuzer, Karl-Anton Furman, Richard R. Stilgenbauer, Stephan Dubowy, Ronald L. Kim, Yeonhee Munugalavadla, Veerendra Lilienweiss, Esther Reinhardt, Hans Christian Cramer, Paula Eichhorst, Barbara Hillmen, Peter O’Brien, Susan M. Pettitt, Andrew R. Hallek, Michael The impact of complex karyotype on the overall survival of patients with relapsed chronic lymphocytic leukemia treated with idelalisib plus rituximab |
| title | The impact of complex karyotype on the overall survival of patients with relapsed chronic lymphocytic leukemia treated with idelalisib plus rituximab |
| title_full | The impact of complex karyotype on the overall survival of patients with relapsed chronic lymphocytic leukemia treated with idelalisib plus rituximab |
| title_fullStr | The impact of complex karyotype on the overall survival of patients with relapsed chronic lymphocytic leukemia treated with idelalisib plus rituximab |
| title_full_unstemmed | The impact of complex karyotype on the overall survival of patients with relapsed chronic lymphocytic leukemia treated with idelalisib plus rituximab |
| title_short | The impact of complex karyotype on the overall survival of patients with relapsed chronic lymphocytic leukemia treated with idelalisib plus rituximab |
| title_sort | impact of complex karyotype on the overall survival of patients with relapsed chronic lymphocytic leukemia treated with idelalisib plus rituximab |
| topic | Letter |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7214265/ https://www.ncbi.nlm.nih.gov/pubmed/31427720 http://dx.doi.org/10.1038/s41375-019-0533-6 |
| work_keys_str_mv | AT kreuzerkarlanton theimpactofcomplexkaryotypeontheoverallsurvivalofpatientswithrelapsedchroniclymphocyticleukemiatreatedwithidelalisibplusrituximab AT furmanrichardr theimpactofcomplexkaryotypeontheoverallsurvivalofpatientswithrelapsedchroniclymphocyticleukemiatreatedwithidelalisibplusrituximab AT stilgenbauerstephan theimpactofcomplexkaryotypeontheoverallsurvivalofpatientswithrelapsedchroniclymphocyticleukemiatreatedwithidelalisibplusrituximab AT dubowyronaldl theimpactofcomplexkaryotypeontheoverallsurvivalofpatientswithrelapsedchroniclymphocyticleukemiatreatedwithidelalisibplusrituximab AT kimyeonhee theimpactofcomplexkaryotypeontheoverallsurvivalofpatientswithrelapsedchroniclymphocyticleukemiatreatedwithidelalisibplusrituximab AT munugalavadlaveerendra theimpactofcomplexkaryotypeontheoverallsurvivalofpatientswithrelapsedchroniclymphocyticleukemiatreatedwithidelalisibplusrituximab AT lilienweissesther theimpactofcomplexkaryotypeontheoverallsurvivalofpatientswithrelapsedchroniclymphocyticleukemiatreatedwithidelalisibplusrituximab AT reinhardthanschristian theimpactofcomplexkaryotypeontheoverallsurvivalofpatientswithrelapsedchroniclymphocyticleukemiatreatedwithidelalisibplusrituximab AT cramerpaula theimpactofcomplexkaryotypeontheoverallsurvivalofpatientswithrelapsedchroniclymphocyticleukemiatreatedwithidelalisibplusrituximab AT eichhorstbarbara theimpactofcomplexkaryotypeontheoverallsurvivalofpatientswithrelapsedchroniclymphocyticleukemiatreatedwithidelalisibplusrituximab AT hillmenpeter theimpactofcomplexkaryotypeontheoverallsurvivalofpatientswithrelapsedchroniclymphocyticleukemiatreatedwithidelalisibplusrituximab AT obriensusanm theimpactofcomplexkaryotypeontheoverallsurvivalofpatientswithrelapsedchroniclymphocyticleukemiatreatedwithidelalisibplusrituximab AT pettittandrewr theimpactofcomplexkaryotypeontheoverallsurvivalofpatientswithrelapsedchroniclymphocyticleukemiatreatedwithidelalisibplusrituximab AT hallekmichael theimpactofcomplexkaryotypeontheoverallsurvivalofpatientswithrelapsedchroniclymphocyticleukemiatreatedwithidelalisibplusrituximab AT kreuzerkarlanton impactofcomplexkaryotypeontheoverallsurvivalofpatientswithrelapsedchroniclymphocyticleukemiatreatedwithidelalisibplusrituximab AT furmanrichardr impactofcomplexkaryotypeontheoverallsurvivalofpatientswithrelapsedchroniclymphocyticleukemiatreatedwithidelalisibplusrituximab AT stilgenbauerstephan impactofcomplexkaryotypeontheoverallsurvivalofpatientswithrelapsedchroniclymphocyticleukemiatreatedwithidelalisibplusrituximab AT dubowyronaldl impactofcomplexkaryotypeontheoverallsurvivalofpatientswithrelapsedchroniclymphocyticleukemiatreatedwithidelalisibplusrituximab AT kimyeonhee impactofcomplexkaryotypeontheoverallsurvivalofpatientswithrelapsedchroniclymphocyticleukemiatreatedwithidelalisibplusrituximab AT munugalavadlaveerendra impactofcomplexkaryotypeontheoverallsurvivalofpatientswithrelapsedchroniclymphocyticleukemiatreatedwithidelalisibplusrituximab AT lilienweissesther impactofcomplexkaryotypeontheoverallsurvivalofpatientswithrelapsedchroniclymphocyticleukemiatreatedwithidelalisibplusrituximab AT reinhardthanschristian impactofcomplexkaryotypeontheoverallsurvivalofpatientswithrelapsedchroniclymphocyticleukemiatreatedwithidelalisibplusrituximab AT cramerpaula impactofcomplexkaryotypeontheoverallsurvivalofpatientswithrelapsedchroniclymphocyticleukemiatreatedwithidelalisibplusrituximab AT eichhorstbarbara impactofcomplexkaryotypeontheoverallsurvivalofpatientswithrelapsedchroniclymphocyticleukemiatreatedwithidelalisibplusrituximab AT hillmenpeter impactofcomplexkaryotypeontheoverallsurvivalofpatientswithrelapsedchroniclymphocyticleukemiatreatedwithidelalisibplusrituximab AT obriensusanm impactofcomplexkaryotypeontheoverallsurvivalofpatientswithrelapsedchroniclymphocyticleukemiatreatedwithidelalisibplusrituximab AT pettittandrewr impactofcomplexkaryotypeontheoverallsurvivalofpatientswithrelapsedchroniclymphocyticleukemiatreatedwithidelalisibplusrituximab AT hallekmichael impactofcomplexkaryotypeontheoverallsurvivalofpatientswithrelapsedchroniclymphocyticleukemiatreatedwithidelalisibplusrituximab |